A World Where Patients No Longer Die
Waiting for Organ Transplants.
Or No More Lives Lost While Waiting For a Transplant

Representative Director and CEO Chieko Mori

Chieko Mori began her career as a Pharmaceutical Technology Researcher at Astellas Pharma Inc. In 2010, she transitioned to the Portfolio Strategy Division, where she took on responsibilities related to business strategy. Subsequently, she served as the Strategic and Policy Secretary to the Global CEO of Astellas Pharma Inc. From 2017 to 2019, Chieko held the position of Vice President of Corporate Planning at Astellas US, where they were responsible for corporate strategy, governance, and regional business development.
Following this, she led global transactions in the Business Development Division at Astellas Pharma. In April 2024, she assumed the role of Chief Business Officer at Corundum Systems Biology Inc. In October 2024, she became the President and CEO of PhenoAI Japan Inc. In January 2025, she was appointed as the Representative Director and CEO of Sennose Therapeutics Inc.

Board Hikaru Saito

Partner, Saisei Ventures
Hikaru Saito is a co-founder of Senno Therapeutics, bringing his expertise in building and expanding initial operations to realize Senno’s vision and realize a world where no more patients die waiting for a transplant.
Dr Saito has been a partner located in Tokyo Japan of Saisei Venture since 2023 and dedicating for creating companies by combination with Japan technologies and western ecosystems. Prior to Saisei, he was working at Astellas Pharma Inc, starting as a research scientist and spent over a decade R&D partnerships and biotechnology investments in the USA. Before Astellas, he was a visiting research fellow of the Institute of Medical Science, the University of Tokyo, JSPS research fellow.

Chairman & Board Jonathan Yeh

Managing Partner, Saisei Ventures
Jonathan is a co-founder and general partner of Saisei Ventures, a leading healthcare focused venture capital firm with operations in the United States and Japan. Jonathan is an early-stage investor focusing on biotechnology and advanced therapies, with particular expertise in the development of cell-based therapies and gene-modified cells. Jonathan’s diverse background spans early-stage venture company creation and investment, strategic business partnering, and fund management. He has co-founded several biotechnology companies and served in various board roles. Previously, Jonathan was a CIHR Post-doctoral Fellow at the IRIC.

Associate Director, Project Management Keisuke Fujitaka

Keisuke Fujitaka started his career as a pharmacology researcher at Mitsubishi-Tanabe Pharma Corporation. He has been involved in non-clinical research on renal, cardiovascular and metabolic diseases for about ten years. In 2018, he transitioned to Regenerative Medicine Development Division of Mitsubishi Chemical Group Company, where he was in charge of non-clinical research, corporate planning and PJ management of cell therapy product. After that, he took on responsibilities to develop the manufacturing process/analytical methods. From 2023, Keisuke moved on to PeptiDream, Inc. and was leading non-oncology pharmacology research including Myostatin inhibitor PJ for obesity treatment as a principal scientist. In April 2025, he joined Senno Therapeutics, Inc. as an associate director and is bringing his expertise in the manufacturing process/analytical methods development and PJ management.

CTO Lisa Fox-Craig

An accomplished cell and gene therapy professional with more than 30 years of experience in the development, cGMP manufacturing, and quality control for cell and gene therapy products. Successfully led development, manufacture and clinical delivery of ex vivo hematopoietic stem cells (HSCs), neural stem cells (NSCs), hepatic progenitor cells (HPC’s), activated T cells, gene-modified T cell & HSC products as well as in vivo adeno-associated virus (AAV) products. Lisa has held leadership roles at Orchard Therapeutics, Sangamo BioSciences, StemCells Inc, and Xcyte Therapies and has experience preparing CMC regulatory submissions with for cell and gene therapy submissions in the US, Canada, Japan, Switzerland and Europe.

Scientific Founder and CSO Hideki Taniguchi

Professor and Director, Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo.
Dr. Taniguchi earned his Ph.D. in Medical Sciences from the Graduate School of Medical Sciences at the University of Tsukuba. After serving as Lecturer in Clinical Medicine (Gastroenterological Surgery) at the University of Tsukuba, he was appointed Professor of Organ Regenerative Medicine at Yokohama City University School of Medicine in 2002. Since 2018, he has been Professor in the Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo. Beginning in 2019, he also took on the role of Director of the Center.
His expertise lies in regenerative medicine, stem cell biology, and transplant surgery. To address transplantation medicine’s most critical unresolved challenge—the absolute shortage of donor organs—he is strategically advancing the development of innovative therapies for liver diseases using human iPS cells.

Corporate planning, Project Management Yusuke Wada

Over 15 years of drug discovery and development experience across small molecules, antibodies, and genetically engineered cell therapies through 15+ projects at Astellas Pharma, including novel target proposals, platform tech development, non-clinical POC, and external collaborations. Since 2018, led iPSC-based cell therapy R&D as Senior Scientist at Universal Cells. In 2024, joined Saisei Ventures as Senior Associate, driving deal sourcing, due diligence, technical strategy, and company creation. Founding member of Senno Therapeutics, supporting business strategy, product planning, and project management.